Grethe Nørskov Rasmussen
Corporate Officer/Principal chez FLUOGUIDE A/S
Fortune : 2 M $ au 31/03/2024
Profil
Grethe Nørskov Rasmussen is currently the Chief Development Officer at FluoGuide A since 2019.
Prior to this, she was the Senior Vice President-Product Development at Ascendis Pharma A from 2008 to 2019.
Before that, she worked as the Vice President-Protein Science at Maxygen, Inc. from 2000 to 2007 and as a Principal at Novo Nordisk A from 1989 to 2000.
Dr. Rasmussen earned her doctorate degree from the Technical University of Denmark in 1989.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FLUOGUIDE A/S
3,06% | 30/09/2023 | 373 185 ( 3,06% ) | 2 M $ | 31/03/2024 |
Postes actifs de Grethe Nørskov Rasmussen
| Sociétés | Poste | Début |
|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 01/01/2019 |
Anciens postes connus de Grethe Nørskov Rasmussen
| Sociétés | Poste | Fin |
|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01/01/2019 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formation de Grethe Nørskov Rasmussen
| Technical University of Denmark | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Entreprise privées | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
